Gapping up
In reaction to strong earnings/guidance: CLNT +20.6%, CAAS +3% (light volume), IOC +2.5% (ticking higher), .
M&A related: BIOF +46.5% (receives proposal for a possible transaction), JNJ +0.6% (Johnson & Johnson announces acceptance of binding offer from The Carlyle Group (CG) to acquire Ortho-Clinical Diagnostics ), SYMC +0.1% (Bloomberg discusses that a breakup may be best thing for SYMC investors).
Select metals/mining stocks trading higher: SVM +5.5%, RIO +1.4%, AG +1.3%, GOLD +0.9%.
A few solar related names showing strength: SOL +4%, YGE +2.3%, CSIQ +2.2%, FSLR+1.1% ( is near mining supply deal with Australia, according to reports), SPWR +0.5%.
Other news: BODY +20.8% (modestly rebounding), MNGA +18.5% (MagneGas and FutureEnergy Sign JV to advance combustion and fuel technologies), HALO +9% (announces that consistent 1 Trial Of Hylenex Recombinant met primary endpoint), INSY +7.8% (Insys Therapeutics Completes Three-for-Two Stock Split Through Stock Dividend), DDR +7.2% (Barron's profiles positive view),AMD +5.7% (still checking), INO +5.5% ( positive comments on Mad Money), LM +5.5% (still checking), CYTR +5% (receives orphan medicinal product designation from the European Commission for Aldoxorubicin in soft tissue sarcoma), BIIB +2.7% (receives FDA approval for ALPROLIX), ING +2.4% (intends to resume dividend payments over the financial year 2015; target pay-out ratio >40%), AMGN +2.1% (reports new detailed data from three Phase 3 pivotal studies show investigational cholesterol-lowering medicine Evolocumab significantly reduced LDL cholesterol By 55-66%), EXAS +1.9% (despite Barron's profiles cautious view), NVS +1.7% ( PARADIGM-HF trial of Novartis' LCZ696 for chronic heart failure closes early based on strength of interim results), FINL+1.7% ( positive comments on Mad Money), AMED +1.2% (announces care center closures and consolidations), AAPL +0.8% (Apple wants $2 bln from Samsung (SSNLF) in latent patent fight, according to reports ), TSLA +0.7% (following 60 Minutes interviews TSLA's Elon Musk). NFLX +0.7% (Barron's profiles positive view), C +0.5% (was hurt by negligent auditing in stress tests, according to reports), C +0.5% (Barron's profiles positive view), GE +0.6% (plans Japan solar plant investment, according to reports), TWTR +0.6% (Twitter ban in Turkey has been overturned), MDT +1.6% (Medtronic's CoreValve System results superior to open-heart surgery at one year in U.S. pivotal trial; Melody Transcatheter Pulmonary Valve shows positive clinical outcomes in real-world study).
Analyst comments: SINA +3.1% (upgraded to Outperform from Sector Perform at Pacific Crest), DEG +2.9% ( upgraded to Overweight from Neutral at JP Morgan), XONE +2.2% (light volume; ExOne upgraded to Buy from Hold at BB&T Capital Mkts), LULU +2.1% (upgraded to Outperform from Neutral at Wedbush), CVA +2% ( upgraded to Strong Buy from Outperform at Raymond James),BIDU +1.7% ( ests raised at Pacific Crest following China trip), BIG +1.6% (upgraded to Buy from Hold at KeyBanc Capital Mkts), VOYA +1.4% ( upgraded to Buy from Neutral at Goldman), VIPS +1.4% (upgraded to Buy from Neutral at Goldman), MCC +1.3% ( upgraded to Outperform from Neutral at Credit Suisse; downgraded to Market Perform from Outperform at Wells Fargo), SAN+1.2% ( upgraded to Hold from Sell at Deutsche Bank), PNRA +1.1% (upgraded to Outperform from Neutral at Wedbush), EIX +0.7% (upgraded to Buy from Neutral at UBS; tgt raised to $60 from $57), TRV +0.3% ( upgraded to Neutral from Sell at Guggenheim),
M&A related: BIOF +46.5% (receives proposal for a possible transaction), JNJ +0.6% (Johnson & Johnson announces acceptance of binding offer from The Carlyle Group (CG) to acquire Ortho-Clinical Diagnostics ), SYMC +0.1% (Bloomberg discusses that a breakup may be best thing for SYMC investors).
Select metals/mining stocks trading higher: SVM +5.5%, RIO +1.4%, AG +1.3%, GOLD +0.9%.
A few solar related names showing strength: SOL +4%, YGE +2.3%, CSIQ +2.2%, FSLR+1.1% ( is near mining supply deal with Australia, according to reports), SPWR +0.5%.
Other news: BODY +20.8% (modestly rebounding), MNGA +18.5% (MagneGas and FutureEnergy Sign JV to advance combustion and fuel technologies), HALO +9% (announces that consistent 1 Trial Of Hylenex Recombinant met primary endpoint), INSY +7.8% (Insys Therapeutics Completes Three-for-Two Stock Split Through Stock Dividend), DDR +7.2% (Barron's profiles positive view),AMD +5.7% (still checking), INO +5.5% ( positive comments on Mad Money), LM +5.5% (still checking), CYTR +5% (receives orphan medicinal product designation from the European Commission for Aldoxorubicin in soft tissue sarcoma), BIIB +2.7% (receives FDA approval for ALPROLIX), ING +2.4% (intends to resume dividend payments over the financial year 2015; target pay-out ratio >40%), AMGN +2.1% (reports new detailed data from three Phase 3 pivotal studies show investigational cholesterol-lowering medicine Evolocumab significantly reduced LDL cholesterol By 55-66%), EXAS +1.9% (despite Barron's profiles cautious view), NVS +1.7% ( PARADIGM-HF trial of Novartis' LCZ696 for chronic heart failure closes early based on strength of interim results), FINL+1.7% ( positive comments on Mad Money), AMED +1.2% (announces care center closures and consolidations), AAPL +0.8% (Apple wants $2 bln from Samsung (SSNLF) in latent patent fight, according to reports ), TSLA +0.7% (following 60 Minutes interviews TSLA's Elon Musk). NFLX +0.7% (Barron's profiles positive view), C +0.5% (was hurt by negligent auditing in stress tests, according to reports), C +0.5% (Barron's profiles positive view), GE +0.6% (plans Japan solar plant investment, according to reports), TWTR +0.6% (Twitter ban in Turkey has been overturned), MDT +1.6% (Medtronic's CoreValve System results superior to open-heart surgery at one year in U.S. pivotal trial; Melody Transcatheter Pulmonary Valve shows positive clinical outcomes in real-world study).
Analyst comments: SINA +3.1% (upgraded to Outperform from Sector Perform at Pacific Crest), DEG +2.9% ( upgraded to Overweight from Neutral at JP Morgan), XONE +2.2% (light volume; ExOne upgraded to Buy from Hold at BB&T Capital Mkts), LULU +2.1% (upgraded to Outperform from Neutral at Wedbush), CVA +2% ( upgraded to Strong Buy from Outperform at Raymond James),BIDU +1.7% ( ests raised at Pacific Crest following China trip), BIG +1.6% (upgraded to Buy from Hold at KeyBanc Capital Mkts), VOYA +1.4% ( upgraded to Buy from Neutral at Goldman), VIPS +1.4% (upgraded to Buy from Neutral at Goldman), MCC +1.3% ( upgraded to Outperform from Neutral at Credit Suisse; downgraded to Market Perform from Outperform at Wells Fargo), SAN+1.2% ( upgraded to Hold from Sell at Deutsche Bank), PNRA +1.1% (upgraded to Outperform from Neutral at Wedbush), EIX +0.7% (upgraded to Buy from Neutral at UBS; tgt raised to $60 from $57), TRV +0.3% ( upgraded to Neutral from Sell at Guggenheim),